The Effect of Inhibition of Interleukin-1 Activity on Vascular and Left Ventricular Function in Patients With Coronary Artery Disease and Coexistent Rheumatoid Arthritis

Trial Profile

The Effect of Inhibition of Interleukin-1 Activity on Vascular and Left Ventricular Function in Patients With Coronary Artery Disease and Coexistent Rheumatoid Arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Anakinra (Primary)
  • Indications Coronary artery disease; Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 29 Aug 2012 Results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
    • 11 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top